Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
暂无分享,去创建一个
Adriano Lazzarin | Edwin DeJesus | Peter Sklar | Jing Zhao | A. Lazzarin | R. Leavitt | R. Pollard | A. Rodgers | Jing Zhao | D. Berger | B. Nguyen | J. Lennox | Richard B Pollard | Michael D Miller | E. Dejesus | M. Dinubile | A. Williams-Diaz | Mark J DiNubile | Jeffrey L Lennox | Jose Valdez Ramalho Madruga | Daniel S Berger | Xia Xu | Angela Williams-Diaz | Anthony J Rodgers | Richard JO Barnard | Bach-Yen Nguyen | Randi Leavitt | Richard J. O. Barnard | J. Madruga | P. Sklar | Xia Xu | M. Miller | Michael D. Miller
[1] C. B. Hare,et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] C. Kovacs,et al. Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.
[3] M. Opravil,et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. , 2008, The Journal of infectious diseases.
[4] H. Teppler,et al. Lack of a Significant Drug Interaction between Raltegravir and Tenofovir , 2008, Antimicrobial Agents and Chemotherapy.
[5] R. Haubrich,et al. Comparison of Neuropsychiatric Side Effects in an Observational Cohort of Efavirenz- and Protease Inhibitor-Treated Patients , 2005, HIV clinical trials.
[6] W. Mcfarland,et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance , 2006, AIDS.
[7] Michael S Saag,et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[8] C. Katlama,et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] J. Reynes,et al. Long‐term assessment of neuropsychiatric adverse reactions associated with efavirenz , 2003, HIV medicine.
[10] D. Hazuda,et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase , 2007, AIDS.
[11] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.
[12] M. Wainberg,et al. HIV transmission and primary drug resistance. , 2006, AIDS reviews.
[13] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] D. Kotler. HIV and Antiretroviral Therapy: Lipid Abnormalities and Associated Cardiovascular Risk in HIV-Infected Patients , 2008, Journal of acquired immune deficiency syndromes.
[15] J A Grobler,et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.
[16] D. E. Smith,et al. Efavirenz and chronic neuropsychiatric symptoms: a cross‐sectional case control study , 2006, HIV medicine.
[17] A. Sharrett,et al. Antiretroviral Therapy is Associated With an Atherogenic Lipoprotein Phenotype Among HIV-1-Infected Men in the Multicenter AIDS Cohort Study , 2008, Journal of acquired immune deficiency syndromes.
[18] P. Narciso,et al. Drug-Class-Wide Resistance to Antiretrovirals in HIV-Infected Patients Failing Therapy: Prevalence, Risk Factors and Virological Outcome , 2005, Antiviral therapy.
[19] D. Hazuda,et al. Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques , 2004, Science.
[20] B. Clotet,et al. Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence , 2005, Journal of acquired immune deficiency syndromes.
[21] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[22] D. Pillay,et al. Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load , 2006, Antiviral therapy.
[23] C. Crumpacker,et al. Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study , 2007, Journal of acquired immune deficiency syndromes.
[24] B. Best,et al. Efavirenz – Still First-line King? , 2008, Expert opinion on drug metabolism & toxicology.
[25] B. Thiers. Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection , 2009 .
[26] B. Hirschel,et al. Initial treatment for HIV infection--an embarrassment of riches. , 2008, The New England journal of medicine.
[27] D. Ward,et al. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. , 2006, AIDS patient care and STDs.
[28] D. Hazuda,et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. , 2008, The New England journal of medicine.
[29] B. Gazzard,et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.
[30] Catia Marzolini,et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.
[31] Lin Shen,et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.
[32] D. Kuritzkes,et al. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. , 2007, The Journal of infectious diseases.
[33] M Nurminen,et al. Comparative analysis of two rates. , 1985, Statistics in medicine.
[34] J. Kahn. Initial Treatment for HIV Infection , 1999 .
[35] K. Buchacz,et al. Changes in Lipid Profile Over 24 Months Among Adults on First-Line Highly Active Antiretroviral Therapy in the Home-Based AIDS Care Program in Rural Uganda , 2008, Journal of acquired immune deficiency syndromes.
[36] Terri Wrin,et al. The prevalence of antiretroviral drug resistance in the United States , 2004, AIDS.
[37] Olga M. Klibanov,et al. Three-class antiretroviral resistance in a patient with acute HIV-1 infection. , 2006, AIDS patient care and STDs.
[38] M C Weinstein,et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.
[39] Michael S Saag,et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.
[40] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[41] F. Gutiérrez,et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] J. Pitt,et al. Time Trends for HIV-1 Antiretroviral Resistance Among Antiretroviral-Experienced and Naive Pregnant Women in New York City During 1991 to Early 2001 , 2007, Journal of acquired immune deficiency syndromes.
[43] C. Katlama,et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial , 2007, The Lancet.
[44] M. Wainberg,et al. Resistance Profiles to Antiretroviral Drugs in HIV-1 Drug-Naive Patients in Argentina , 2001, Antiviral therapy.
[45] Michael P. Busch,et al. Trends in Antiretroviral Drug Resistance and Clade Distributions Among HIV-1--Infected Blood Donors in Sao Paulo, Brazil , 2006, Journal of acquired immune deficiency syndromes.
[46] S. Spector,et al. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. , 2006, The Journal of infectious diseases.
[47] Edward P Acosta,et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.